2025-524715-37-00招募中1 期
A study of IDE892 as monotherapy and combination in MTAP-deleted Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 73
- 试验地点
- 19
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Ideaya Admin
Scientific
Ideaya Biosciences Inc.
研究点 (19)
Loading locations...
相似试验
招募中
2 期
Study with IDE849 for patients with DLL3 positive cancer, including small cell lung cancerDLL3 Expressing Tumors Including Small Cell Lung Cancer2025-523438-24-00Ideaya Biosciences Inc.35
尚未招募
3 期
A clinical trial to study the effect of two modalities of treatment in combination and sole in patients with Diabetic RetinopathyCTRI/2024/09/073792Sri Devaraj Urs Academy of higher education and research50
招募中
1 期
IBI343 Combined With Chemotherapy in Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT07692750Zhejiang Cancer Hospital56
Unknown
2 期
评价伊立替康脂质体（Ⅱ）或伊立替康联合 5-氟尿嘧 啶、亚叶酸钙、贝伐珠单抗用于既往一线标准治疗失败 的转移性结直肠癌（mCRC）： 一项随机化、开放标签、多中心临床研究ChiCTR2400088240自筹
招募中
2 期
Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancerExtensive-Stage Small Cell Lung Cancer2025-523972-21-00Fortvita Biologics (USA) Inc.30